Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its price objective cut by Morgan Stanley from $164.00 to $159.00 in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target points to a potential upside of 13.81% from the stock’s previous close.
ALNY has been the topic of a number of other research reports. SVB Leerink raised their target price on shares of Alnylam Pharmaceuticals from $96.00 to $98.00 and gave the stock a “market perform” rating in a report on Wednesday, June 15th. Oppenheimer reaffirmed an “outperform” rating and set a $205.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 6th. Citigroup dropped their target price on Alnylam Pharmaceuticals from $211.00 to $206.00 in a report on Friday. Guggenheim cut Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 27th. Finally, HC Wainwright boosted their target price on Alnylam Pharmaceuticals from $400.00 to $430.00 in a report on Monday, May 2nd. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $212.18.
Alnylam Pharmaceuticals Stock Down 2.7 %
NASDAQ:ALNY traded down $3.81 during mid-day trading on Friday, reaching $139.71. The stock had a trading volume of 1,169 shares, compared to its average volume of 824,151. The company has a market capitalization of $16.88 billion, a price-to-earnings ratio of -19.16 and a beta of 0.80. Alnylam Pharmaceuticals has a 1-year low of $117.58 and a 1-year high of $212.00. The stock’s 50 day simple moving average is $139.03 and its two-hundred day simple moving average is $146.61. The company has a debt-to-equity ratio of 1.69, a current ratio of 4.27 and a quick ratio of 4.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.67). Alnylam Pharmaceuticals had a negative return on equity of 137.44% and a negative net margin of 101.46%. The business had revenue of $224.80 million during the quarter, compared to the consensus estimate of $256.06 million. During the same period in the prior year, the business earned ($1.61) EPS. The business’s revenue was up 1.9% on a year-over-year basis. Equities analysts anticipate that Alnylam Pharmaceuticals will post -7.05 EPS for the current year.
Insider Activity at Alnylam Pharmaceuticals
In related news, EVP Tolga Tanguler sold 1,754 shares of the company’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $150.00, for a total value of $263,100.00. Following the sale, the executive vice president now owns 1,754 shares of the company’s stock, valued at $263,100. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.40% of the stock is currently owned by insiders.
Institutional Trading of Alnylam Pharmaceuticals
Several large investors have recently added to or reduced their stakes in ALNY. Capital World Investors grew its stake in Alnylam Pharmaceuticals by 1,781.1% during the first quarter. Capital World Investors now owns 5,999,674 shares of the biopharmaceutical company’s stock worth $979,687,000 after buying an additional 5,680,728 shares during the last quarter. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $215,229,000. Deep Track Capital LP lifted its position in shares of Alnylam Pharmaceuticals by 4,062.9% during the first quarter. Deep Track Capital LP now owns 463,663 shares of the biopharmaceutical company’s stock worth $75,712,000 after purchasing an additional 475,363 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Alnylam Pharmaceuticals by 17.3% during the first quarter. The Manufacturers Life Insurance Company now owns 1,997,762 shares of the biopharmaceutical company’s stock worth $326,975,000 after purchasing an additional 295,092 shares in the last quarter. Finally, Eaton Vance Management lifted its position in shares of Alnylam Pharmaceuticals by 606.7% during the first quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock worth $50,005,000 after purchasing an additional 262,893 shares in the last quarter. 92.39% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.